This week we’re starting a new weekly news video called Psychedellux which will cover the psychedelic company news of the week.
This week the first psychedelic stock ETF (exchange-traded fund) will begin trading on the Canadian NEO exchange under the ticker PSYK on January 27. The base currency will be Canadian dollars. The ETF will be managed by Canadian financial services company Horizons ETF Management and it will be focused on the emerging psychedelics opportunity led by life science and pharmaceutical companies.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) closed on an underwritten public offering that is expected to raise approximately $33.5 million.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has submitted a formal application to list its common shares on the NASDAQ Stock Exchange.
NeonMind Biosciences Inc. (CSE: NEON) has appointed pharmaceutical executive Robert Tessarolo as its President and Chief Executive Officer.
As the race to own the psilocybin market heats up, MagicMed Industries Inc. (CSE: MGIC reserved) announced that it has completed the establishment of the psilocybin-derivatives patent portfolio of the Psybrary and the launch of the Candidate Selection program. The company said that Psybrary is a proprietary physical and knowledgebase collection of novel psychedelic-derivative drug candidates, manufacturing methods, pharmacological data, and patent filings that protect all of the above.
Ehave, Inc. (OTC Pink: EHVVF) announced it is exploring how palliative patients could benefit from its Ketamine home delivery platform, KetaDASH.